These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 19574008)

  • 1. Prevalence of acute adverse reactions to gadobutrol--a highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials.
    Forsting M; Palkowitsch P
    Eur J Radiol; 2010 Jun; 74(3):e186-92. PubMed ID: 19574008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.
    Voth M; Rosenberg M; Breuer J
    Invest Radiol; 2011 Nov; 46(11):663-71. PubMed ID: 21623211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients.
    Hahn G; Sorge I; Gruhn B; Glutig K; Hirsch W; Bhargava R; Furtner J; Born M; Schröder C; Ahlström H; Kaiser S; Moritz JD; Kunze CW; Shroff M; Stokland E; Trnkova ZJ; Schultze-Mosgau M; Reif S; Bacher-Stier C; Mentzel HJ
    Invest Radiol; 2009 Dec; 44(12):776-83. PubMed ID: 19858730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial.
    Hammerstingl R; Adam G; Ayuso JR; Van Beers B; Belfiore G; Bellin MF; Bongartz G; Ernst O; Frericks B; Giuseppetti G; Heinz-Peer G; Laghi A; Martin J; Pering C; Reimer P; Richter GM; Roemer FW; Schäfer FK; Vilgrain V; Vogl TJ; Weishaupt D; Wall A; Zech CJ; Tombach B
    Invest Radiol; 2009 Mar; 44(3):168-76. PubMed ID: 19169143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadobutrol for contrast-enhanced magnetic resonance imaging in elderly patients: review of the safety profile from clinical trial, post-marketing surveillance, and pharmacovigilance data.
    Endrikat J; Schwenke C; Prince MR
    Clin Radiol; 2015 Jul; 70(7):743-51. PubMed ID: 25933719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of acute reactions to iopromide: postmarketing surveillance study of 74,717 patients.
    Kopp AF; Mortele KJ; Cho YD; Palkowitsch P; Bettmann MA; Claussen CD
    Acta Radiol; 2008 Oct; 49(8):902-11. PubMed ID: 18651252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance.
    Shellock FG; Parker JR; Venetianer C; Pirovano G; Spinazzi A
    Invest Radiol; 2006 Jun; 41(6):500-9. PubMed ID: 16763468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)].
    Herborn CU; Jäger-Booth I; Lodemann KP; Spinazzi A; Goyen M
    Rofo; 2009 Jul; 181(7):652-7. PubMed ID: 19291607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study].
    Vogl TJ; Friebe CE; Balzer T; Mack MG; Steiner S; Schedel H; Pegios W; Lanksch W; Banzer D; Felix R
    Radiologe; 1995 Aug; 35(8):508-16. PubMed ID: 7568795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses.
    de Kerviler E; Maravilla K; Meder JF; Naggara O; Dubourdieu C; Jullien V; Desché P
    Invest Radiol; 2016 Sep; 51(9):544-51. PubMed ID: 27504794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Gadobutrol: Results From 42 Clinical Phase II to IV Studies and Postmarketing Surveillance After 29 Million Applications.
    Endrikat J; Vogtlaender K; Dohanish S; Balzer T; Breuer J
    Invest Radiol; 2016 Sep; 51(9):537-43. PubMed ID: 26964075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-reactive protein levels and clinical symptoms following gadolinium administration in hemodialysis patients.
    Schieren G; Tokmak F; Lefringhausen L; van Bracht M; Perings C; Willers R; Günsel A; Kemper F; Wiesmüller GA; Rump LC
    Am J Kidney Dis; 2008 Jun; 51(6):976-86. PubMed ID: 18501785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients.
    Morgan DE; Spann JS; Lockhart ME; Winningham B; Bolus DN
    Radiology; 2011 Apr; 259(1):109-16. PubMed ID: 21248237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine.
    Anzalone N; Gerevini S; Scotti R; Vezzulli P; Picozzi P
    Acta Radiol; 2009 Oct; 50(8):933-40. PubMed ID: 19626475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple drug exposure as a risk factor for the seriousness of adverse drug reactions.
    Macedo AF; Alves C; Craveiro N; Marques FB
    J Nurs Manag; 2011 Apr; 19(3):395-9. PubMed ID: 21507111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using a 1 M Gd-chelate (gadobutrol) for total-body three-dimensional MR angiography: preliminary experience.
    Goyen M; Herborn CU; Vogt FM; Kröger K; Verhagen R; Yang F; Bosk S; Debatin JF; Ruehm SG
    J Magn Reson Imaging; 2003 May; 17(5):565-71. PubMed ID: 12720266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients.
    Abujudeh HH; Rolls H; Kaewlai R; Agarwal S; Gebreananya ZA; Saini S; Schaefer PW; Kay J
    J Magn Reson Imaging; 2009 Dec; 30(6):1335-40. PubMed ID: 19937927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 Tesla.
    Giesel FL; Mehndiratta A; Risse F; Rius M; Zechmann CM; von Tengg-Kobligk H; Gerigk L; Kauczor HU; Politi M; Essig M; Griffiths PD; Wilkinson ID
    Acta Radiol; 2009 Jun; 50(5):521-30. PubMed ID: 19337867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic and delayed contrast enhancement in upper abdominal MRI studies: comparison of gadoxetic acid and gadobutrol.
    Zizka J; Klzo L; Ferda J; Mrklovský M; Bukac J
    Eur J Radiol; 2007 May; 62(2):186-91. PubMed ID: 17367974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of gadobutrol in over 23,000 patients: the GARDIAN study, a global multicentre, prospective, non-interventional study.
    Prince MR; Lee HG; Lee CH; Youn SW; Lee IH; Yoon W; Yang B; Wang H; Wang J; Shih TT; Huang GS; Lirng JF; Palkowitsch P;
    Eur Radiol; 2017 Jan; 27(1):286-295. PubMed ID: 26960538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.